Phase II study of S-1+CPT-11+Bevacizumab as second-line therapy in metastatic colorectal cancer which has prior therapy of S-1+L-OHP+Bevacizumab
收藏NIAID Data Ecosystem2026-03-08 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2630432
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Bevacizumab 7.5mg/kg/tri-week CPT-11 150mg/m2/tri-week S-1 40-60mg/twice/day(day1-15)/tri-week
Primary outcome(s): Progression-free survival
Study Design: Single arm Non-randomized
创建时间：
2014-06-15
